Analysis shows no extra risks in infliximab for Crohn's

10/15/2008 | MedPage Today (free registration)

An analysis of the 6,273-patient Crohn's Therapy Resource, Evaluation and Assessment Tool, or TREAT, registry found taking infliximab is not any riskier for Crohn's patients than other immunomodulating drugs. The researchers did find the risk of death increased by 86% among prednisone users and doubled for patients given narcotic analgesics.

View Full Article in:

MedPage Today (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC